论文部分内容阅读
志贺杆菌是导致大量小儿腹泻,加重低收入国家疾病负担的主要病原菌之一。目前没有疫苗可用,而现有的候选疫苗只限于部分有效且存在血清型特异性。志贺菌III型分泌系统蛋白Ipa B和Ipa D,由于在不同志贺菌中的保守性,成为研发具有广谱保护的亚单位疫苗的候选物。本文用双突变体大肠杆菌不耐热肠毒素(dmLT)作为佐剂,利用显微操作针皮内注射的方法研究了Ipa B和Ipa D的免疫原性和保护效力。就Ipa B
Shigella is one of the major pathogenic bacteria that cause large amounts of pediatric diarrhea and aggravate the disease burden in low-income countries. Currently no vaccine is available, and the current vaccine candidates are only partially effective and have serotype specificities. Shigella Type III secretion system proteins, Ipa B and Ipa D, became candidates for the development of subunit vaccines with broad-spectrum protection due to their conservatism in different Shigella strains. In this study, Ipa B and Ipa D immunogenicity and protective efficacy were investigated by intradermal injection of microspheres using the double mutant Escherichia coli heat-labile enterotoxin (dmLT) as an adjuvant. Ipa B